Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Laboratoires Thea60 enrolled

Overview

The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Seasonal Allergic Conjunctivitis

Interventions

T1210DRUG

2 drops T1210 once a day

Olopatadine hydrochlorideDRUG

2 drops once a day Olopatadine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * Conjunctivitis allergic conjunctivitis Exclusion Criteria: * Severe ocular allergy * Vernal keratoconjunctivitis

Locations (1)

Pierre Huguet

Clermont-Ferrand, France

Outcomes

Primary Outcomes

Change from baseline of the score of tearing

Time frame: Day 28

Change from baseline of the score of itching

Time frame: Day 28

Change from baseline of the score of conjunctival hyperaemia

Time frame: Day 28

Secondary Outcomes

Global local tolerance assessment by the Investigator and the patient

Time frame: Day 7

Global local tolerance assessment by the Investigator and the patient

Time frame: Day 28

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.